董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Graham George Lumsden | 男 | Chief Executive Officer and Executive Director | 59 | 72.66万美元 | 未持股 | 2018-12-31 |
| Richard Cecil Eversfield Morgan | 男 | Non-Executive Chairman | 79 | 11.35万美元 | 未持股 | 2018-12-31 |
| Charlotta Ginman Horrell | 女 | Non-Executive Director | 53 | 6.97万美元 | 未持股 | 2018-12-31 |
| Jonathan Gold | 男 | Chief Financial Officer and Executive Director | 46 | 88.15万美元 | 未持股 | 2018-12-31 |
| Zaki Hosny | 男 | Non-Executive Director | 70 | 6.25万美元 | 未持股 | 2018-12-31 |
| Bruce Andrew Williams | 男 | Non-Executive Interim Chairman | 64 | 6.40万美元 | 未持股 | 2018-12-31 |
| Craig T. Albanese | 男 | Non-Executive Director | 57 | 5.75万美元 | 未持股 | 2018-12-31 |
| Mary Lake Polan | 女 | Non-Executive Director | 75 | 6.00万美元 | 未持股 | 2018-12-31 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Graham George Lumsden | 男 | Chief Executive Officer and Executive Director | 59 | 72.66万美元 | 未持股 | 2018-12-31 |
| Jonathan Gold | 男 | Chief Financial Officer and Executive Director | 46 | 88.15万美元 | 未持股 | 2018-12-31 |
| David Huang | 男 | Chief Medical Officer | 44 | 57.61万美元 | 未持股 | 2018-12-31 |
董事简历
中英对照 | 中文 | 英文- Graham George Lumsden
-
Graham George Lumsden自2013年5月担任公司的首席执行官。在加入本公司之前，1985年至2011年，Lumsden博士是Merck & Co., Inc.的一位资深高管，他在那里获得了各种商业的全球领导地位。2012年至2014年他担任TieMed LLC的首席执行官。2012年至2014年他担任Carnethy Consulting LLC的首席。Lumsden博士还是兽医皇家学院（MRCVS）的成员。他于1998年在英国伦敦的营销特许学会（Chartered Institute of Marketing）获得市场营销研究生文凭，于1982年在苏格兰爱丁堡的兽医研究皇家学院（Royal School of Veterinary Studies）获得兽药和外科手术的BVM＆S。
Graham George Lumsden has served as our Chief Executive Officer and Executive Director since May 2013. Prior to joining the Company, Dr. Lumsden was a senior executive at Merck & Co., Inc. NYSE: MRK from 1985 to 2011 where he held various commercial worldwide leadership positions, with global responsibility for osteoporosis and then contraceptives. He also served as Chief Executive Officer of TieMed LLC from 2012 to 2014 and as a principal of Carnethy Consulting LLC from 2012 to 2014. Dr. Lumsden is a member of the Royal College of Veterinary Surgeons (MRCVS). He obtained a postgraduate diploma in marketing from the Chartered Institute of Marketing in London, United Kingdom in 1998 and his BVM&S in veterinary medicine and surgery from the Royal (Dick) School of Veterinary Studies in Edinburgh, Scotland in 1982. With his extensive industry experience, Dr. Lumsden provides valuable scientific, operational and strategic direction as Chief Executive Officer and Director. - Graham George Lumsden自2013年5月担任公司的首席执行官。在加入本公司之前，1985年至2011年，Lumsden博士是Merck & Co., Inc.的一位资深高管，他在那里获得了各种商业的全球领导地位。2012年至2014年他担任TieMed LLC的首席执行官。2012年至2014年他担任Carnethy Consulting LLC的首席。Lumsden博士还是兽医皇家学院（MRCVS）的成员。他于1998年在英国伦敦的营销特许学会（Chartered Institute of Marketing）获得市场营销研究生文凭，于1982年在苏格兰爱丁堡的兽医研究皇家学院（Royal School of Veterinary Studies）获得兽药和外科手术的BVM＆S。
- Graham George Lumsden has served as our Chief Executive Officer and Executive Director since May 2013. Prior to joining the Company, Dr. Lumsden was a senior executive at Merck & Co., Inc. NYSE: MRK from 1985 to 2011 where he held various commercial worldwide leadership positions, with global responsibility for osteoporosis and then contraceptives. He also served as Chief Executive Officer of TieMed LLC from 2012 to 2014 and as a principal of Carnethy Consulting LLC from 2012 to 2014. Dr. Lumsden is a member of the Royal College of Veterinary Surgeons (MRCVS). He obtained a postgraduate diploma in marketing from the Chartered Institute of Marketing in London, United Kingdom in 1998 and his BVM&S in veterinary medicine and surgery from the Royal (Dick) School of Veterinary Studies in Edinburgh, Scotland in 1982. With his extensive industry experience, Dr. Lumsden provides valuable scientific, operational and strategic direction as Chief Executive Officer and Director.
- Richard Cecil Eversfield Morgan
-
Richard Cecil Eversfield Morgan自2004年担任公司董事会的非执行主席。他也是Amphion Capital Partners LLC，Morgan先生自2005年联合创立并任职的，继任事务所Amphion Innovations plc的首席执行官。在他的职业生涯中，Morgan先生直接参与了超过35家生物制药、医疗保健和IT产业的创立和发展，包括Celgene Corporation（NASDAQ：CELG）（自1987年至2016年）和Pharmaceuticals, Inc.。他也是Amphion Partners LLC的合伙人（前身为Wolfensohn Partners, LP），他保持着合作但不再是处于活跃状态的职位。在加入Wolfensohn之前，Morgan先生在Schroders plc花了15年时间，一家英国商业银行，作为他创立的Schroders Strategy Group的董事会一员。Morgan先生目前担任其他四个Amphion合伙公司的主席（Axcess International Inc.（自2004年5月），FireStar Software, Inc.（自2005年6月），PrivateMarkets, Inc.（自2007年）和WellGen, Inc.（自2007年11月））并且是DataTern, Inc.的董事（自2008年）。他以一等荣誉毕业于新西兰奥克兰大学（University of Auckland, New Zealand）的B级工程学。1982年，他完成了哈佛商学院（Harvard Business School）的高级管理课程。
Richard Cecil Eversfield Morgan has served as the Non-Executive Chairman of our board of directors since 2004. He is also Chief Executive Officer of Amphion Innovations plc the successor firm to Amphion Capital Partners LLC, which Mr. Morgan co-founded, a position he has held since 2005. Over the course of his career, Mr. Morgan has been directly involved in the start-up and development of more than 35 companies in the biopharma, healthcare, and IT industries, including Celgene Corporation (NASDAQ: CELG) (from 1987 to 2016) and Sequus Pharmaceuticals, Inc. He was also the managing general partner of Amphion Partners LLC (formerly known as Wolfensohn Partners, LP), a position which he retains, although the partnership is no longer active. Before joining Wolfensohn, Mr. Morgan spent 15 years with Schroders plc, a British merchant bank, as a member of the board and head of the Schroder Strategy Group, which he founded. Mr. Morgan currently serves as Chairman of four other Amphion Partner Companies (Axcess International Inc. (since May 2004), FireStar Software, Inc. (since June 2005), PrivateMarkets, Inc. (since 2007) and WellGen, Inc. (since November 2007) and is also a director of DataTern, Inc. (since 2008). He graduated with a B. Engineering First Class Honors from the University of Auckland, New Zealand. In 1982 he completed the Advanced Management Program at Harvard Business School. - Richard Cecil Eversfield Morgan自2004年担任公司董事会的非执行主席。他也是Amphion Capital Partners LLC，Morgan先生自2005年联合创立并任职的，继任事务所Amphion Innovations plc的首席执行官。在他的职业生涯中，Morgan先生直接参与了超过35家生物制药、医疗保健和IT产业的创立和发展，包括Celgene Corporation（NASDAQ：CELG）（自1987年至2016年）和Pharmaceuticals, Inc.。他也是Amphion Partners LLC的合伙人（前身为Wolfensohn Partners, LP），他保持着合作但不再是处于活跃状态的职位。在加入Wolfensohn之前，Morgan先生在Schroders plc花了15年时间，一家英国商业银行，作为他创立的Schroders Strategy Group的董事会一员。Morgan先生目前担任其他四个Amphion合伙公司的主席（Axcess International Inc.（自2004年5月），FireStar Software, Inc.（自2005年6月），PrivateMarkets, Inc.（自2007年）和WellGen, Inc.（自2007年11月））并且是DataTern, Inc.的董事（自2008年）。他以一等荣誉毕业于新西兰奥克兰大学（University of Auckland, New Zealand）的B级工程学。1982年，他完成了哈佛商学院（Harvard Business School）的高级管理课程。
- Richard Cecil Eversfield Morgan has served as the Non-Executive Chairman of our board of directors since 2004. He is also Chief Executive Officer of Amphion Innovations plc the successor firm to Amphion Capital Partners LLC, which Mr. Morgan co-founded, a position he has held since 2005. Over the course of his career, Mr. Morgan has been directly involved in the start-up and development of more than 35 companies in the biopharma, healthcare, and IT industries, including Celgene Corporation (NASDAQ: CELG) (from 1987 to 2016) and Sequus Pharmaceuticals, Inc. He was also the managing general partner of Amphion Partners LLC (formerly known as Wolfensohn Partners, LP), a position which he retains, although the partnership is no longer active. Before joining Wolfensohn, Mr. Morgan spent 15 years with Schroders plc, a British merchant bank, as a member of the board and head of the Schroder Strategy Group, which he founded. Mr. Morgan currently serves as Chairman of four other Amphion Partner Companies (Axcess International Inc. (since May 2004), FireStar Software, Inc. (since June 2005), PrivateMarkets, Inc. (since 2007) and WellGen, Inc. (since November 2007) and is also a director of DataTern, Inc. (since 2008). He graduated with a B. Engineering First Class Honors from the University of Auckland, New Zealand. In 1982 he completed the Advanced Management Program at Harvard Business School.
- Charlotta Ginman Horrell
-
Charlotta Ginman Horrell自2015年担任公司的非执行董事。Ginman-Horrell女士担任Polar Capital Technology Trust plc（自2015年2月），Pacific Assets Trust plc（自2014年10月）与Consort Medical plc（自2015年2月）的非执行董事，并作为Polar Capital Technology Trust plc与Pacific Assets Trust plc。的审计委员会主席。Ginman-Horrell女士曾任Wolfson Microelectronics plc（自2013年7月到2014年8月）和Kromek plc（自2014年2月至2016年）的非执行董事。她在投资银行（瑞银，德意志银行和摩根大通（UBS, Deutsche Bank, and JPMorgan））和电信业（诺基亚（自2012年6月至2014年6月）与Vertu有限公司（自2012年6月至2013年3月））担任高级职务。Ginman-Horrell女士还持有赫尔辛基瑞典学院（Swedish School）经济学与工商管理硕士学位，在英格兰和威尔士是合格注册会计师。
Charlotta Ginman Horrell has served as a non-executive director of the Company since April 2015. Ms. Ginman-Horrell is also a non-executive director of Polar Capital Technology Trust plc since February 2015 Pacific Assets Trust plc (since October 2014), Consort Medical plc (since February 2015), Unicorn AIM VCT plc (since July 2016) and acts as the audit committee chair for Polar Capital Technology Trust plc and Pacific Assets Trust plc. Ms. Ginman-Horrell was formerly a non-executive director of Wolfson Microelectronics plc (from July 2013 to August 2014) and Kromek plc (from February 2014 to December 2015). She held senior positions in the investment banking (UBS, Deutsche Bank, and JPMorgan) and telecom sectors (Nokia Corporation and Vertu Ltd). A qualified chartered accountant in England and Wales, Ms. Ginman-Horrell also holds a MSc. in Economics from the Swedish School of Economics and Business Administration in Helsinki. - Charlotta Ginman Horrell自2015年担任公司的非执行董事。Ginman-Horrell女士担任Polar Capital Technology Trust plc（自2015年2月），Pacific Assets Trust plc（自2014年10月）与Consort Medical plc（自2015年2月）的非执行董事，并作为Polar Capital Technology Trust plc与Pacific Assets Trust plc。的审计委员会主席。Ginman-Horrell女士曾任Wolfson Microelectronics plc（自2013年7月到2014年8月）和Kromek plc（自2014年2月至2016年）的非执行董事。她在投资银行（瑞银，德意志银行和摩根大通（UBS, Deutsche Bank, and JPMorgan））和电信业（诺基亚（自2012年6月至2014年6月）与Vertu有限公司（自2012年6月至2013年3月））担任高级职务。Ginman-Horrell女士还持有赫尔辛基瑞典学院（Swedish School）经济学与工商管理硕士学位，在英格兰和威尔士是合格注册会计师。
- Charlotta Ginman Horrell has served as a non-executive director of the Company since April 2015. Ms. Ginman-Horrell is also a non-executive director of Polar Capital Technology Trust plc since February 2015 Pacific Assets Trust plc (since October 2014), Consort Medical plc (since February 2015), Unicorn AIM VCT plc (since July 2016) and acts as the audit committee chair for Polar Capital Technology Trust plc and Pacific Assets Trust plc. Ms. Ginman-Horrell was formerly a non-executive director of Wolfson Microelectronics plc (from July 2013 to August 2014) and Kromek plc (from February 2014 to December 2015). She held senior positions in the investment banking (UBS, Deutsche Bank, and JPMorgan) and telecom sectors (Nokia Corporation and Vertu Ltd). A qualified chartered accountant in England and Wales, Ms. Ginman-Horrell also holds a MSc. in Economics from the Swedish School of Economics and Business Administration in Helsinki.
- Jonathan Gold
-
Jonathan Gold自2015年4月一直担任公司的非执行董事。Gold先生自2012年8月是JEG Capital LLC，一个家庭办公与资产管理公司的常务董事。此前，他是Federated Kaufmann Funds的投资组合经理（2004年至2012年）。在此之前，Gold先生是Amphion Capital Partners LLC（前身为Amphion Innovations plc）（从1996年至2004年）和Wolfensohn Partners（James D. Wolfensohn Inc.的原始附属公司）（自1995年至2004年），那些他活跃于融资和早期成长的生命科学和信息技术公司的合伙人。在他事业生涯的早期，Gold先生是拥有超过10亿股权和抵押贷款的房地产投资管理公司Prudential's Realty Group（1995年至1996年）的金融分析师。获得了纽约大学斯特恩商学院（New York University's Stern School）科学与金融学工商管理硕士学位。
Jonathan Gold was a co-founder of the Company and had served as a non-executive director since 2004. Effective February 2 2018 Mr. Gold assumed an executive role as Chief Financial Officer. Mr. Gold is a managing director of JEG Capital LLC, a family office and asset manager since August 2012. Previously he was a portfolio manager for the Federated Kaufmann Funds from 2004 to 2012. Prior to that, Mr. Gold was a partner at Amphion Capital Partners LLC the predecessor to Amphion Innovations plc from 1996 to 2004 and Wolfensohn Partners (originally affiliates of James D. Wolfensohn Inc.) (from 1995 to 2004), where he was active in financing and growing early stage life sciences and information technology companies. Early in his career, Mr. Gold was a financial analyst for Prudential’s Realty Group (from 1995 to 1996), which managed over $10 billion in equity and mortgage real estate investments. Mr. Gold received his Bachelor of Science and MBA in Finance from New York University’s Stern School of Business. With his professional financial expertise and business acumen, Mr. Gold provides valuable guidance and strategic direction as Chief Financial Offer and Executive and Director. - Jonathan Gold自2015年4月一直担任公司的非执行董事。Gold先生自2012年8月是JEG Capital LLC，一个家庭办公与资产管理公司的常务董事。此前，他是Federated Kaufmann Funds的投资组合经理（2004年至2012年）。在此之前，Gold先生是Amphion Capital Partners LLC（前身为Amphion Innovations plc）（从1996年至2004年）和Wolfensohn Partners（James D. Wolfensohn Inc.的原始附属公司）（自1995年至2004年），那些他活跃于融资和早期成长的生命科学和信息技术公司的合伙人。在他事业生涯的早期，Gold先生是拥有超过10亿股权和抵押贷款的房地产投资管理公司Prudential's Realty Group（1995年至1996年）的金融分析师。获得了纽约大学斯特恩商学院（New York University's Stern School）科学与金融学工商管理硕士学位。
- Jonathan Gold was a co-founder of the Company and had served as a non-executive director since 2004. Effective February 2 2018 Mr. Gold assumed an executive role as Chief Financial Officer. Mr. Gold is a managing director of JEG Capital LLC, a family office and asset manager since August 2012. Previously he was a portfolio manager for the Federated Kaufmann Funds from 2004 to 2012. Prior to that, Mr. Gold was a partner at Amphion Capital Partners LLC the predecessor to Amphion Innovations plc from 1996 to 2004 and Wolfensohn Partners (originally affiliates of James D. Wolfensohn Inc.) (from 1995 to 2004), where he was active in financing and growing early stage life sciences and information technology companies. Early in his career, Mr. Gold was a financial analyst for Prudential’s Realty Group (from 1995 to 1996), which managed over $10 billion in equity and mortgage real estate investments. Mr. Gold received his Bachelor of Science and MBA in Finance from New York University’s Stern School of Business. With his professional financial expertise and business acumen, Mr. Gold provides valuable guidance and strategic direction as Chief Financial Offer and Executive and Director.
- Zaki Hosny
-
Zaki Hosny自2006年以来担任公司的非执行董事。Hosny先生是生命科学公司的独立顾问。Hosny先生大部分时间都致力于Merck & Co, Inc. NASDAQ：MRK（从1998年至2007年）世界范围内的市场营销和综合管理职位，包括公司在欧洲主要市场业务的管理责任。他还曾在美国担任高级营销职位和几个欧洲国家的综合管理职位，负责全球心血管与特许经营权的的市场推广责任，并密切参与公司的一些主要产品的临床开发。Hosny先生是Motif Biosciences, Inc.的首席执行官（自2006年至2013年）和公司董事会副主席（自2006年至2013年）。Hosny先生目前是Albright Stonebridge Group，一家总部设在华盛顿的战略咨询公司的高级顾问，并且是英国Mettle Consulting Limited和Mansfield Consulting LLC新泽西地区的Harel Consulting的顾问。Hosny先生常驻于新泽西州普林斯顿，是剑桥大学（Cambridge University）历史与法律的文学硕士毕业生。
Zaki Hosny has served as a non-executive director of the Company since 2006. Mr. Hosny is an independent consultant to life sciences companies. Mr. Hosny spent most of his career at Merck & Co, Inc. NYSE: MRK from 1998 to 2007 in marketing and general management positions around the world, including management responsibility for the company’s business in major markets in Europe. He also held senior marketing positions in the United States and several European countries in general management, marketing roles with worldwide responsibility for cardiovascular and other franchises, and was closely involved in the clinical development of some of the company’s major products. Mr. Hosny was Chief Executive Officer of Motif BioSciences, Inc. from 2006 to 2013 and Deputy Chairman of its Board of Directors from 2006 to 2013. Mr. Hosny is currently a Senior Advisor to the Albright Stonebridge Group, a strategic consultancy firm based in Washington, DC and a consultant to Harel Consulting of New Jersey, Mettle Consulting Limited of the United Kingdom and Mansfield Consulting LLC. Mr. Hosny is based in Princeton, New Jersey, and is a graduate of Cambridge University with an M.A. in History and Law. Mr. Hosny provides a wealth of strategic insight based on his extensive experience in the pharmaceutical and biotechnology industries. - Zaki Hosny自2006年以来担任公司的非执行董事。Hosny先生是生命科学公司的独立顾问。Hosny先生大部分时间都致力于Merck & Co, Inc. NASDAQ：MRK（从1998年至2007年）世界范围内的市场营销和综合管理职位，包括公司在欧洲主要市场业务的管理责任。他还曾在美国担任高级营销职位和几个欧洲国家的综合管理职位，负责全球心血管与特许经营权的的市场推广责任，并密切参与公司的一些主要产品的临床开发。Hosny先生是Motif Biosciences, Inc.的首席执行官（自2006年至2013年）和公司董事会副主席（自2006年至2013年）。Hosny先生目前是Albright Stonebridge Group，一家总部设在华盛顿的战略咨询公司的高级顾问，并且是英国Mettle Consulting Limited和Mansfield Consulting LLC新泽西地区的Harel Consulting的顾问。Hosny先生常驻于新泽西州普林斯顿，是剑桥大学（Cambridge University）历史与法律的文学硕士毕业生。
- Zaki Hosny has served as a non-executive director of the Company since 2006. Mr. Hosny is an independent consultant to life sciences companies. Mr. Hosny spent most of his career at Merck & Co, Inc. NYSE: MRK from 1998 to 2007 in marketing and general management positions around the world, including management responsibility for the company’s business in major markets in Europe. He also held senior marketing positions in the United States and several European countries in general management, marketing roles with worldwide responsibility for cardiovascular and other franchises, and was closely involved in the clinical development of some of the company’s major products. Mr. Hosny was Chief Executive Officer of Motif BioSciences, Inc. from 2006 to 2013 and Deputy Chairman of its Board of Directors from 2006 to 2013. Mr. Hosny is currently a Senior Advisor to the Albright Stonebridge Group, a strategic consultancy firm based in Washington, DC and a consultant to Harel Consulting of New Jersey, Mettle Consulting Limited of the United Kingdom and Mansfield Consulting LLC. Mr. Hosny is based in Princeton, New Jersey, and is a graduate of Cambridge University with an M.A. in History and Law. Mr. Hosny provides a wealth of strategic insight based on his extensive experience in the pharmaceutical and biotechnology industries.
- Bruce Andrew Williams
-
Bruce Andrew Williams自2004年2月一直担任公司的非执行董事。 从2010年11月至2011年5月，Williams先生曾担任WellGen，Inc.的首席执行官。从2010年3月至2010年11月，Williams先生曾担任WellGen, Inc.的商业运营部负责人。从2001年2月至2005年3月，Williams先生曾担任Genta Incorporated的高级副总裁，负责销售和营销。他在那里主导了产品的许可和共同开发/共同市场的与Aventis公司谈判与协议。从1996年6月至2001年2月，Williams先生曾担任Celgene Corporation的销售和营销高级副总裁。他在那里建立了公司的商业和配送基础设施来支持推出其第一款产品THALOMID（沙利度胺）。从1989年7月至1996年6月Williams先生曾担任Ortho Biotech Products LP的执行董事，在那里他领导了Johnson & Johnson subsidiary的主打产品Procrit（阿法依伯汀）从前期推出市场上的第五个年头开始的营销。自2004年2月Williams先生担任Motif, Inc. (本公司的子公司)以及Afaxys, Inc.的董事。Williams先生于1982年在Columbia Business School获得了财务和会计工商管理硕士学位并于1976年在Syracuse University获得文学学士学位。
Bruce Andrew Williams has served as a non-executive director of the Company since February 2004 and as non-executive interim Chairman since March 18 2019. Mr. Williams served as the Chief Executive Officer of WellGen, Inc. from November 2010 to May 2011 and Head of Commercial Operations at Corcept Therapeutics Incorporated from March 2010 to November 2010. Mr. Williams was Senior Vice President, Sales and Marketing at Genta Incorporated from February 2001 to March 2005 where he led the negotiation of a licensing and co-development/co-marketing agreement with Aventis for the company’s lead product. Mr. Williams was previously Senior Vice President of Sales and Marketing at Celgene Corporation from June 1996 to February 2001 where he built the company’s commercial and distribution infrastructure to support the launch of its first product, Thalomid (thalidomide). Mr. Williams was an executive director of Ortho Biotech Products LP (from July 1989 to June 1996), where he led the marketing of this Johnson & Johnson subsidiary’s lead product, Procrit (epoetin alfa), from pre-launch to its fifth year on the market. Mr. Williams currently serves on the boards of Motif, Inc., the Company’s subsidiary (since February 2004), and Afaxys, Inc. (since February 2011). Mr. Williams obtained his MBA in finance and accounting from Columbia Business School in 1982 and obtained his BA in biology from Syracuse University in 1976. With his wealth of experience in the pharmaceutical and biotechnology industries, as well as his marketing background, Mr. William provides valuable operational and strategic guidance as Interim Chairman and Non-executive Director. - Bruce Andrew Williams自2004年2月一直担任公司的非执行董事。 从2010年11月至2011年5月，Williams先生曾担任WellGen，Inc.的首席执行官。从2010年3月至2010年11月，Williams先生曾担任WellGen, Inc.的商业运营部负责人。从2001年2月至2005年3月，Williams先生曾担任Genta Incorporated的高级副总裁，负责销售和营销。他在那里主导了产品的许可和共同开发/共同市场的与Aventis公司谈判与协议。从1996年6月至2001年2月，Williams先生曾担任Celgene Corporation的销售和营销高级副总裁。他在那里建立了公司的商业和配送基础设施来支持推出其第一款产品THALOMID（沙利度胺）。从1989年7月至1996年6月Williams先生曾担任Ortho Biotech Products LP的执行董事，在那里他领导了Johnson & Johnson subsidiary的主打产品Procrit（阿法依伯汀）从前期推出市场上的第五个年头开始的营销。自2004年2月Williams先生担任Motif, Inc. (本公司的子公司)以及Afaxys, Inc.的董事。Williams先生于1982年在Columbia Business School获得了财务和会计工商管理硕士学位并于1976年在Syracuse University获得文学学士学位。
- Bruce Andrew Williams has served as a non-executive director of the Company since February 2004 and as non-executive interim Chairman since March 18 2019. Mr. Williams served as the Chief Executive Officer of WellGen, Inc. from November 2010 to May 2011 and Head of Commercial Operations at Corcept Therapeutics Incorporated from March 2010 to November 2010. Mr. Williams was Senior Vice President, Sales and Marketing at Genta Incorporated from February 2001 to March 2005 where he led the negotiation of a licensing and co-development/co-marketing agreement with Aventis for the company’s lead product. Mr. Williams was previously Senior Vice President of Sales and Marketing at Celgene Corporation from June 1996 to February 2001 where he built the company’s commercial and distribution infrastructure to support the launch of its first product, Thalomid (thalidomide). Mr. Williams was an executive director of Ortho Biotech Products LP (from July 1989 to June 1996), where he led the marketing of this Johnson & Johnson subsidiary’s lead product, Procrit (epoetin alfa), from pre-launch to its fifth year on the market. Mr. Williams currently serves on the boards of Motif, Inc., the Company’s subsidiary (since February 2004), and Afaxys, Inc. (since February 2011). Mr. Williams obtained his MBA in finance and accounting from Columbia Business School in 1982 and obtained his BA in biology from Syracuse University in 1976. With his wealth of experience in the pharmaceutical and biotechnology industries, as well as his marketing background, Mr. William provides valuable operational and strategic guidance as Interim Chairman and Non-executive Director.
- Craig T. Albanese
-
暂无中文简介
Craig T. Albanese has served as a non-executive director of the Company since May 2017. Dr. Albanese has 25 years of clinical and administrative experience focusing on children and women’s health, primarily in the Stanford Children’s Hospital, New-York Presbyterian Hospital, Morgan Stanley Children’s Hospital and the Sloane Hospital for Women. He is currently Senior Vice President and Chief Operating Officer at New York-Presbyterian/Morgan Stanley Children’s Hospital and Sloane Hospital for Women. He has had a distinguished clinical career to date having published 161 peer review articles, contributed 57 book chapters, and risen to Professor of Surgery in Pediatrics, Obstetrics and Gynecology. He has combined his clinical career with success in hospital administrative positions where he has had a pivotal role in setting up networks of physicians, support, and educational services across a number of hospitals and medical institutions to provide integrated clinical and support services for increasing numbers of patients in a very cost effective way. After receiving his medical degree from SUNY-Health Science Center in Brooklyn, Dr. Albanese was a resident, and later, chief resident in general surgery at Mount Sinai Medical Center. Following his residency, he completed pediatric general surgery and critical care/research fellowships at Children’s Hospital of Pittsburgh. He also holds a Master’s in Business Administration from the Leavey School of Business at Santa Clara University. -
暂无中文简介
- Craig T. Albanese has served as a non-executive director of the Company since May 2017. Dr. Albanese has 25 years of clinical and administrative experience focusing on children and women’s health, primarily in the Stanford Children’s Hospital, New-York Presbyterian Hospital, Morgan Stanley Children’s Hospital and the Sloane Hospital for Women. He is currently Senior Vice President and Chief Operating Officer at New York-Presbyterian/Morgan Stanley Children’s Hospital and Sloane Hospital for Women. He has had a distinguished clinical career to date having published 161 peer review articles, contributed 57 book chapters, and risen to Professor of Surgery in Pediatrics, Obstetrics and Gynecology. He has combined his clinical career with success in hospital administrative positions where he has had a pivotal role in setting up networks of physicians, support, and educational services across a number of hospitals and medical institutions to provide integrated clinical and support services for increasing numbers of patients in a very cost effective way. After receiving his medical degree from SUNY-Health Science Center in Brooklyn, Dr. Albanese was a resident, and later, chief resident in general surgery at Mount Sinai Medical Center. Following his residency, he completed pediatric general surgery and critical care/research fellowships at Children’s Hospital of Pittsburgh. He also holds a Master’s in Business Administration from the Leavey School of Business at Santa Clara University.
- Mary Lake Polan
-
Mary Lake Polan自2004年2月一直担任公司的非执行董事。Polan博士是2014年以来耶鲁大学医学院系产科，妇科，生殖和科学医学院的临床教授。从2008至2014年Polan博士担任哥伦比亚大学医学院妇产科系兼职教授。1990年至2006年她曾担任斯坦福大学医学院妇产科的系主任和名誉教授。Polan博士专门从事生殖内分泌和不孕不育及相关妇科患者和更年期荷尔蒙的问题。Polan博士担任惠氏（Wyeth）（NYSE：WYE）的董事会成员（1995-2009），其收购Pfizer Inc.，目前是Quidel Corp.（NASDAQ： QDEL）的董事（自1993年），并在几个私人持有的生命科学公司担任董事会成员。她主持的妇女健康科学顾问委员会为宝洁公司和私人生命科学公司的其他几个顾问委员会成员。她还担任Golden Seeds常务董事，投资于妇女的天使投资集团牵头的企业。她从康涅狄格学院获得学士学位，生物物理与生物化学分子哲学博士，从耶鲁大学医学博士，并从耶鲁大学部妇产科医学院获得了她的居住和生殖内分泌奖学金。Polan博士持有加州大学伯克利分校（the Fisher Center Policy Advisory Board）的公共卫生硕士学位（妇幼卫生项目）。
Mary Lake Polan,served as an Adjunct Professor in the Department of Obstetrics and Gynecology at Columbia University School of Medicine from 2007 to 2014 and then in 2015, she rejoined the Department of Obstetrics and Gynecology at Yale University School of Medicine as a Professor of Clinical Obstetrics, Gynecology and Reproductive Sciences. Dr. Polan previously served as a Professor and Chair Emerita of the Department of Gynecology and Obstetrics at Stanford University School of Medicine from 1990 to 2005, and before that served on the faculty at Yale University. Dr. Polan received a B.A. degree from Connecticut College, a Ph.D. in Molecular Biophysics and Biochemistry and an M.D. from Yale University School of Medicine and her Master in Public Health from the University of California, Berkeley. Dr. Polan remained at Yale New Haven Hospital for her residency in Obstetrics and Gynecology, followed by a Reproductive Endocrine Fellowship. Dr. Polan also serves as a director at the following private companies: NX Prenatal Inc., Or-Genix Therapeutics, Inc., Residents Diagnostics, Inc. and MiraDx, Inc. - Mary Lake Polan自2004年2月一直担任公司的非执行董事。Polan博士是2014年以来耶鲁大学医学院系产科，妇科，生殖和科学医学院的临床教授。从2008至2014年Polan博士担任哥伦比亚大学医学院妇产科系兼职教授。1990年至2006年她曾担任斯坦福大学医学院妇产科的系主任和名誉教授。Polan博士专门从事生殖内分泌和不孕不育及相关妇科患者和更年期荷尔蒙的问题。Polan博士担任惠氏（Wyeth）（NYSE：WYE）的董事会成员（1995-2009），其收购Pfizer Inc.，目前是Quidel Corp.（NASDAQ： QDEL）的董事（自1993年），并在几个私人持有的生命科学公司担任董事会成员。她主持的妇女健康科学顾问委员会为宝洁公司和私人生命科学公司的其他几个顾问委员会成员。她还担任Golden Seeds常务董事，投资于妇女的天使投资集团牵头的企业。她从康涅狄格学院获得学士学位，生物物理与生物化学分子哲学博士，从耶鲁大学医学博士，并从耶鲁大学部妇产科医学院获得了她的居住和生殖内分泌奖学金。Polan博士持有加州大学伯克利分校（the Fisher Center Policy Advisory Board）的公共卫生硕士学位（妇幼卫生项目）。
- Mary Lake Polan,served as an Adjunct Professor in the Department of Obstetrics and Gynecology at Columbia University School of Medicine from 2007 to 2014 and then in 2015, she rejoined the Department of Obstetrics and Gynecology at Yale University School of Medicine as a Professor of Clinical Obstetrics, Gynecology and Reproductive Sciences. Dr. Polan previously served as a Professor and Chair Emerita of the Department of Gynecology and Obstetrics at Stanford University School of Medicine from 1990 to 2005, and before that served on the faculty at Yale University. Dr. Polan received a B.A. degree from Connecticut College, a Ph.D. in Molecular Biophysics and Biochemistry and an M.D. from Yale University School of Medicine and her Master in Public Health from the University of California, Berkeley. Dr. Polan remained at Yale New Haven Hospital for her residency in Obstetrics and Gynecology, followed by a Reproductive Endocrine Fellowship. Dr. Polan also serves as a director at the following private companies: NX Prenatal Inc., Or-Genix Therapeutics, Inc., Residents Diagnostics, Inc. and MiraDx, Inc.
高管简历
中英对照 | 中文 | 英文- Graham George Lumsden
Graham George Lumsden自2013年5月担任公司的首席执行官。在加入本公司之前，1985年至2011年，Lumsden博士是Merck & Co., Inc.的一位资深高管，他在那里获得了各种商业的全球领导地位。2012年至2014年他担任TieMed LLC的首席执行官。2012年至2014年他担任Carnethy Consulting LLC的首席。Lumsden博士还是兽医皇家学院（MRCVS）的成员。他于1998年在英国伦敦的营销特许学会(Chartered Institute of Marketing)获得市场营销研究生文凭，于1982年在苏格兰爱丁堡的兽医研究皇家学院(Royal School of Veterinary Studies)获得兽药和外科手术的BVM＆S。
Graham George Lumsden has served as our Chief Executive Officer and Executive Director since May 2013. Prior to joining the Company, Dr. Lumsden was a senior executive at Merck & Co., Inc. NYSE: MRK from 1985 to 2011 where he held various commercial worldwide leadership positions, with global responsibility for osteoporosis and then contraceptives. He also served as Chief Executive Officer of TieMed LLC from 2012 to 2014 and as a principal of Carnethy Consulting LLC from 2012 to 2014. Dr. Lumsden is a member of the Royal College of Veterinary Surgeons (MRCVS). He obtained a postgraduate diploma in marketing from the Chartered Institute of Marketing in London, United Kingdom in 1998 and his BVM&S in veterinary medicine and surgery from the Royal (Dick) School of Veterinary Studies in Edinburgh, Scotland in 1982. With his extensive industry experience, Dr. Lumsden provides valuable scientific, operational and strategic direction as Chief Executive Officer and Director.- Graham George Lumsden自2013年5月担任公司的首席执行官。在加入本公司之前，1985年至2011年，Lumsden博士是Merck & Co., Inc.的一位资深高管，他在那里获得了各种商业的全球领导地位。2012年至2014年他担任TieMed LLC的首席执行官。2012年至2014年他担任Carnethy Consulting LLC的首席。Lumsden博士还是兽医皇家学院（MRCVS）的成员。他于1998年在英国伦敦的营销特许学会(Chartered Institute of Marketing)获得市场营销研究生文凭，于1982年在苏格兰爱丁堡的兽医研究皇家学院(Royal School of Veterinary Studies)获得兽药和外科手术的BVM＆S。
- Graham George Lumsden has served as our Chief Executive Officer and Executive Director since May 2013. Prior to joining the Company, Dr. Lumsden was a senior executive at Merck & Co., Inc. NYSE: MRK from 1985 to 2011 where he held various commercial worldwide leadership positions, with global responsibility for osteoporosis and then contraceptives. He also served as Chief Executive Officer of TieMed LLC from 2012 to 2014 and as a principal of Carnethy Consulting LLC from 2012 to 2014. Dr. Lumsden is a member of the Royal College of Veterinary Surgeons (MRCVS). He obtained a postgraduate diploma in marketing from the Chartered Institute of Marketing in London, United Kingdom in 1998 and his BVM&S in veterinary medicine and surgery from the Royal (Dick) School of Veterinary Studies in Edinburgh, Scotland in 1982. With his extensive industry experience, Dr. Lumsden provides valuable scientific, operational and strategic direction as Chief Executive Officer and Director.
- Jonathan Gold
Jonathan Gold自2015年4月一直担任公司的非执行董事。Gold先生自2012年8月是JEG Capital LLC，一个家庭办公与资产管理公司的常务董事。此前，他是Federated Kaufmann Funds的投资组合经理（2004年至2012年）。在此之前，Gold先生是Amphion Capital Partners LLC（前身为Amphion Innovations plc）（从1996年至2004年）和Wolfensohn Partners（James D. Wolfensohn Inc.的原始附属公司）（自1995年至2004年），那些他活跃于融资和早期成长的生命科学和信息技术公司的合伙人。在他事业生涯的早期，Gold先生是拥有超过10亿股权和抵押贷款的房地产投资管理公司Prudential's Realty Group（1995年至1996年）的金融分析师。获得了纽约大学斯特恩商学院（New York University's Stern School）科学与金融学工商管理硕士学位。
Jonathan Gold was a co-founder of the Company and had served as a non-executive director since 2004. Effective February 2 2018 Mr. Gold assumed an executive role as Chief Financial Officer. Mr. Gold is a managing director of JEG Capital LLC, a family office and asset manager since August 2012. Previously he was a portfolio manager for the Federated Kaufmann Funds from 2004 to 2012. Prior to that, Mr. Gold was a partner at Amphion Capital Partners LLC the predecessor to Amphion Innovations plc from 1996 to 2004 and Wolfensohn Partners (originally affiliates of James D. Wolfensohn Inc.) (from 1995 to 2004), where he was active in financing and growing early stage life sciences and information technology companies. Early in his career, Mr. Gold was a financial analyst for Prudential’s Realty Group (from 1995 to 1996), which managed over $10 billion in equity and mortgage real estate investments. Mr. Gold received his Bachelor of Science and MBA in Finance from New York University’s Stern School of Business. With his professional financial expertise and business acumen, Mr. Gold provides valuable guidance and strategic direction as Chief Financial Offer and Executive and Director.- Jonathan Gold自2015年4月一直担任公司的非执行董事。Gold先生自2012年8月是JEG Capital LLC，一个家庭办公与资产管理公司的常务董事。此前，他是Federated Kaufmann Funds的投资组合经理（2004年至2012年）。在此之前，Gold先生是Amphion Capital Partners LLC（前身为Amphion Innovations plc）（从1996年至2004年）和Wolfensohn Partners（James D. Wolfensohn Inc.的原始附属公司）（自1995年至2004年），那些他活跃于融资和早期成长的生命科学和信息技术公司的合伙人。在他事业生涯的早期，Gold先生是拥有超过10亿股权和抵押贷款的房地产投资管理公司Prudential's Realty Group（1995年至1996年）的金融分析师。获得了纽约大学斯特恩商学院（New York University's Stern School）科学与金融学工商管理硕士学位。
- Jonathan Gold was a co-founder of the Company and had served as a non-executive director since 2004. Effective February 2 2018 Mr. Gold assumed an executive role as Chief Financial Officer. Mr. Gold is a managing director of JEG Capital LLC, a family office and asset manager since August 2012. Previously he was a portfolio manager for the Federated Kaufmann Funds from 2004 to 2012. Prior to that, Mr. Gold was a partner at Amphion Capital Partners LLC the predecessor to Amphion Innovations plc from 1996 to 2004 and Wolfensohn Partners (originally affiliates of James D. Wolfensohn Inc.) (from 1995 to 2004), where he was active in financing and growing early stage life sciences and information technology companies. Early in his career, Mr. Gold was a financial analyst for Prudential’s Realty Group (from 1995 to 1996), which managed over $10 billion in equity and mortgage real estate investments. Mr. Gold received his Bachelor of Science and MBA in Finance from New York University’s Stern School of Business. With his professional financial expertise and business acumen, Mr. Gold provides valuable guidance and strategic direction as Chief Financial Offer and Executive and Director.
- David Huang
David Huang自2014年10月担任公司首席医疗官。在加入本公司之前，Huang博士担任在休斯敦的几个初创公司开发抗感染和退伍军人事务医学中心的临床顾问，他将继续做急诊医学主治医生。在他担任临床顾问的角色之前，Huang博士曾担任ContraFect Corporation（NASDAQ：CFRX）（2011至2014年）前首席医疗官，在那里他对生物抗感染，包括噬菌体裂解酶和单克隆抗体的发展具有责任。Huang博士也带领Pfizer Inc.（NYSE：PFE）（2008至2011年）和Boehringer-Ingelheim（2005年至2008年）抗感染的药物开发组。Huang博士曾担任贝勒医学院的助理教授，目前担任罗格斯大学新泽西州医学院的助理临床教授。他精通的设计，执行和结束阶段出1-3为抗菌和抗病毒制剂的临床试验。Huang博士完成了在得克萨斯大学休斯敦医学院的医学课程，并拥有德克萨斯大学休斯顿西南大学的内科实习和团契传染病在贝勒医学院。
David Huang has served as our Chief Medical Officer since October 2014. Prior to joining the Company, Dr. Huang served as a clinical consultant for several start-up companies developing anti-infectives and as an attending physician in emergency medicine at the Veterans Affairs Medical Center in Houston, which he continues to do. Prior to his clinical consultant role, Dr. Huang served as the former Chief Medical Officer at ContraFect Corporation NASDAQ: CFRX from 2011 to 2014 where he had responsibility for the development of biologic anti-infectives, including bacteriophage lysins and monoclonal antibodies. Dr. Huang also led drug development groups in anti-infectives at Pfizer Inc. NYSE: PFE from 2008 to 2011 and Boehringer Ingelheim (from 2005 to 2008). Dr. Huang has 15 years of clinical, academic and research experience in medicine and in the subspecialty of infectious diseases. He served as a faculty member at Baylor College of Medicine and is currently an adjunct Assistant Professor at Rutgers New Jersey Medical School (since 2009). He is well versed in the design, execution and close out of Phase 1-3 clinical trials for both antibacterial and antiviral agents. Dr. Huang completed his medical school at the University of Texas at Houston Medical School, and completed his internship and residency in internal medicine at the University of Texas at Southwestern and fellowship in infectious diseases at Baylor College of Medicine. He is board certified in both internal medicine and infectious diseases.- David Huang自2014年10月担任公司首席医疗官。在加入本公司之前，Huang博士担任在休斯敦的几个初创公司开发抗感染和退伍军人事务医学中心的临床顾问，他将继续做急诊医学主治医生。在他担任临床顾问的角色之前，Huang博士曾担任ContraFect Corporation（NASDAQ：CFRX）（2011至2014年）前首席医疗官，在那里他对生物抗感染，包括噬菌体裂解酶和单克隆抗体的发展具有责任。Huang博士也带领Pfizer Inc.（NYSE：PFE）（2008至2011年）和Boehringer-Ingelheim（2005年至2008年）抗感染的药物开发组。Huang博士曾担任贝勒医学院的助理教授，目前担任罗格斯大学新泽西州医学院的助理临床教授。他精通的设计，执行和结束阶段出1-3为抗菌和抗病毒制剂的临床试验。Huang博士完成了在得克萨斯大学休斯敦医学院的医学课程，并拥有德克萨斯大学休斯顿西南大学的内科实习和团契传染病在贝勒医学院。
- David Huang has served as our Chief Medical Officer since October 2014. Prior to joining the Company, Dr. Huang served as a clinical consultant for several start-up companies developing anti-infectives and as an attending physician in emergency medicine at the Veterans Affairs Medical Center in Houston, which he continues to do. Prior to his clinical consultant role, Dr. Huang served as the former Chief Medical Officer at ContraFect Corporation NASDAQ: CFRX from 2011 to 2014 where he had responsibility for the development of biologic anti-infectives, including bacteriophage lysins and monoclonal antibodies. Dr. Huang also led drug development groups in anti-infectives at Pfizer Inc. NYSE: PFE from 2008 to 2011 and Boehringer Ingelheim (from 2005 to 2008). Dr. Huang has 15 years of clinical, academic and research experience in medicine and in the subspecialty of infectious diseases. He served as a faculty member at Baylor College of Medicine and is currently an adjunct Assistant Professor at Rutgers New Jersey Medical School (since 2009). He is well versed in the design, execution and close out of Phase 1-3 clinical trials for both antibacterial and antiviral agents. Dr. Huang completed his medical school at the University of Texas at Houston Medical School, and completed his internship and residency in internal medicine at the University of Texas at Southwestern and fellowship in infectious diseases at Baylor College of Medicine. He is board certified in both internal medicine and infectious diseases.